Abstracts tagged "pain"

Abstract Number: 1609 • ACR Convergence 2023
Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study
Danilo Perretta¹, Daniele Mauro¹, flavia riccio¹, valentina marino¹, emma scoppetta², Francesco ciccia¹ and rosella tirri¹, ¹University of Campania - Luigi Vanvitelli, Naples, Italy, ²University of Salerno, Salerno, Italy
Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…
Abstract Number: 1839 • ACR Convergence 2023
Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting
Styliani Tsiami¹, Elena Enax-Krumova², Dietrich Sturm³, Matthias Vorgerd², Bjoern Buehring⁴, Juergen Braun⁵ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Neurologische Klinik Universitätsklinikum Bergmannsheil Bochum, Ruhr-University Bochum, Bochum, Germany, ³Agaplesion Bethesda - Krankenhaus, Wuppertal, Klinik für Neurologie, Wuppertal, Germany, ⁴Krankenhaus St. Josef, Wuppertal, Klinik für Internistische Rheumatologie, Wuppertal, Germany, ⁵Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Small fiber neuropathy (SFN), a polyneuropathy (PNP) affecting A-delta and C-fibers has been described in patients with fibromyalgia (FM). Different patterns of small fiber…
Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Maxime Dougados¹, Peter C. Taylor², David Gruben³ and Meriem Kessouri⁴, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., Paris, France
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
Abstract Number: 0817 • ACR Convergence 2023
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Bedru Abafita¹, Ambrish Singh¹, Dawn Aitken¹, Steffany Moonaz², Andrew J Palmer¹, Leigh Blizzard¹, Changhai Ding¹, Stan Drummen¹, Graeme Jones³, Kim Bennell⁴ and Benny Samuel Antony¹, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, ³Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, ⁴University of Melbourne, Melbourne, Australia
Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
Abstract Number: 1191 • ACR Convergence 2023
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee
Guang-Liang Jiang¹ and Feng Xu², ¹Xgene Pharmaceutical Inc., Lexington, MA, ²Xgene Pharmaceutical Inc., Altos Hills, CA
Background/Purpose: Globally osteoarthritis affects about 302 million patients, knee osteoarthritis accounts for 263 million and ranks the highest in disability and pain compared to OA…
Abstract Number: 1610 • ACR Convergence 2023
Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial
Michael Gendreau¹, Andrea Chadwick², Lance McCracken³, David Williams⁴, Daniel Clauw⁵, Juan Luciano⁶, Yifei Dai⁷, Nicolette Vega⁸, Zunera Ghalib⁸, Kristen Guthrie⁸, Allison Kraus⁸, Michael Rosenbluth⁸, Jennifer Zomnir⁹, Dana Reddy¹⁰ and Lesley arnold¹¹, ¹Gendreau Consulting, LLC, Poway, CA, ²Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, ³Department of Psychology, Uppsala University, Uppsala, Sweden, ⁴Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, ⁷Swing Therapeutics, Gainesville, FL, ⁸Swing Therapeutics, San Francisco, CA, ⁹DelRicht Resesarch, Mckinney, TX, ¹⁰Curavit, Scarsdale, NY, ¹¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…
Abstract Number: 1844 • ACR Convergence 2023
Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey
Jutta Richter¹, Aurelia Beichert², Tim Filla², Matthias Schneider³, Joerg Distler⁴ and Inna Frohne², ¹Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, ²Clinic for Rheumatology and Hiller Research Unit University Clinic Duesseldorf, Düsseldorf, Germany, ³Heinrich-Heine-Universitaet Duesseldorf, Duesseldorf, Germany, ⁴Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
Background/Purpose: There is an increasing demand from patients for medical cannabis in the German population [1]. Although medical cannabis might be used to treat pain…
Abstract Number: 2219 • ACR Convergence 2023
Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis
Dafne Capelusnik¹, Elena Nikiphorou², Annelies Boonen³, Désirée van der Heijde⁴, Robert BM Landewé⁵, Astrid van Tubergen⁶ and Sofia Ramiro⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²King's College London, London, United Kingdom, ³Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: In the context of the recent update of the ASAS core outcomes set (COS), the preferred comparative validity of the measurement instruments to assess…
Abstract Number: 0316 • ACR Convergence 2023
Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis
Lindsey MacFarlane¹, Hanna Mass¹, Catherine Yang¹, Jose Acosta Julbe¹, Antonia Chen¹, Jeffrey Lange¹, Morgan Jones¹, Faith Selzer¹, Jamie Collins¹, Elena Losina² and Jeffrey Katz¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Pain in knee osteoarthritis (OA) is multifactorial and influenced by factors including pain sensitization. Most literature on sensitization and OA has contrasted persons with…
Abstract Number: 0818 • ACR Convergence 2023
Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial
Eric Grigsby¹, Stephen D. Collins², Leonard Kapural³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Neurovations Clinical Research, Napa, CA, ²Xalud Therapeutics, Inc., Chicago, IL, ³Center for Clinical Research, Winston-Salem, NC, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. Unfortunately, relatively short…
Abstract Number: 1194 • ACR Convergence 2023
Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain
Kent Kwoh¹, Frank Roemer², Erin Ashbeck³ and Ali Guermazi⁴, ¹University of Arizona, Tucson, AZ, ²Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, ³University of Arizona Arthritis Center, Tucson, AZ, ⁴Boston University, Boston, MA
Background/Purpose: Subchondral bone marrow lesions (BMLs) have been associated with incident and progressive pain and reported to fluctuate along with concurrent fluctuations in symptoms. While…
Abstract Number: 1614 • ACR Convergence 2023
Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial
Caroline Maindet¹, Anne Dumolard², Mélanie Veloso², Mario Barmaki³, Rodrigue Deleens⁴, Raphaël Gonon-Demoulian⁵, Alberta Lorenzi-Pernot⁶, Mireille Michel-Cherqui⁷, Alain Serrie⁸, Stanislas Velliet⁹ and Jean-Luc Bosson², ¹University Hospital Grenoble Alpes, Grenoble, France, ²Grenoble Alpes University Hospital, Grenoble, France, ³Médipôle Lyon Villeurbanne, Lyon, France, ⁴Rouen University Hospital, Rouen, France, ⁵Montpellier University Hospital, Montpellier, France, ⁶Neurology private practice, Mornant, France, ⁷Foch hospital, Suresnes, France, ⁸Paris University Hospital, Paris, Guinea, ⁹Valenciennes hospital, Valenciennes, France
Background/Purpose: Fibromyalgia is a chronic syndrome with symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, and cognitive impairment. While first-line recommendation…
Abstract Number: 1925 • ACR Convergence 2023
Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Helena Abodeely¹, Sandy Hong⁶, Arundathi Jayatilleke⁷, Petar Lenert⁸, T. Shawn Sato¹, Yongdong (Dan) Zhao⁹, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon¹⁰ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital For Special Surgery, New York, NY, ⁴Indiana University, Indianapolis, IN, ⁵Ohio State University Hospital, Columbus, OH, ⁶University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁷Temple University, Philadelphia, PA, ⁸University of Iowa Hospitals and Clinics, Iowa City, IA, ⁹University of Washington, Seattle, WA, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Musculoskeletal pain is a key symptom experienced by patients with SAPHO and chronic nonbacterial osteomyelitis (SAPHO-CNO), yet its relation to disease activity assessment remains…
Abstract Number: 2230 • ACR Convergence 2023
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
Laura Coates¹, Robert BM Landewé², Iain McInnes³, Philip J. Mease⁴, Christopher T Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Alice B. Gottlieb¹¹, Richard B. Warren¹², Barbara Ink¹³, Rajan Bajracharya¹³, Jason Coarse¹⁴ and Joseph Merola¹⁵, ¹University of Oxford, Oxford, United Kingdom, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ³University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan, ⁸Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁰Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, ¹²Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹³UCB Pharma, Slough, United Kingdom, ¹⁴UCB Pharma, Morrisville, NC, ¹⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has shown superior efficacy to 16 weeks (wks) vs placebo…

« Previous Page
1
…
6
7
8
9
10
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].